alpelisib

alpelisib

Blog Article

1. Basic Product Identification

INN Name: Alpelisib

Brand Name: Piqray

Therapeutic Class: PI3K inhibitor (PI3Kα selective)

Route: Oral (tablet)

Target Therapy Area: Oncology (breast cancer)

Primary indication:

HR-positive HER2-negative breast cancer with PIK3CA mutation

2. Therapeutic Knowledge

Alpelisib is used in:

Advanced/metastatic breast cancer

Always in combination with fulvestrant

For PIK3CA-mutated tumors only

Key concept:

? First-in-class PI3Kα isoform-specific targeted therapy

3. Mechanism of Action (MOA)

Alpelisib selectively inhibits PI3K alpha (PI3Kα).

Pathway:

Blocks PI3K → AKT → mTOR signaling cascade

Effects:

↓ tumor cell proliferation

↓ survival signaling

Induces apoptosis in PIK3CA-mutant cancer cells

Key insight:

? Targets driver mutation pathway in oncogenesis

4. Pharmacokinetics (ADME)

Absorption

Oral bioavailability moderate

Food has minimal clinically significant effect

Distribution

Moderate plasma protein binding (~80%)

Metabolism

Primarily hepatic metabolism (CYP3A4 involvement minor)

Excretion

Fecal (major)

Urinary (minor)

Half-life:

~8–9 hours

5. Dosage & Administration

Standard regimen:

300 mg once daily (oral tablet)

Combination:

Always with fulvestrant (endocrine therapy)

Administration rules:

Take with food

Same time daily

Dose reduction required in toxicity (hyperglycemia management)

6. Formulation Knowledge

Dosage form:

Film-coated oral tablets

Key formulation challenges:

Low solubility

High-dose strength (oncology dosing)

Stability in humid environments

Technologies used:

Solid dispersion

Particle size reduction

Film coating for stability

7. Raw Materials Knowledge

API:

Alpelisib (synthetic small molecule kinase inhibitor)

Excipients:

Microcrystalline cellulose

Mannitol

Sodium starch glycolate

Magnesium stearate

Film coating polymers (HPMC-based)

Critical issues:

Control of polymorphism

Impurity control (genotoxic impurity risk monitoring)

8. Manufacturing Process Knowledge

API synthesis:

Multi-step heterocyclic organic synthesis

Kinase inhibitor scaffold construction

Purification via crystallization & chromatography

Tablet manufacturing:

Blending (API + excipients)

Dry granulation preferred (stability)

Compression

Film coating

Critical controls:

Uniformity (high-dose oncology tablet)

Impurity profile control (ICH Q3A/Q3B strict)

9. Analytical & QC Knowledge

Key QC tests:

HPLC assay

Impurity profiling (trace-level sensitivity)

Dissolution testing (biorelevant media)

Content uniformity

Water content (KF)

Residual solvents (GC)

Advanced techniques:

LC-MS/MS for impurity tracking

Stability-indicating methods

10. Regulatory Knowledge

Approval status:

FDA approved (targeted oncology indication)

EMA approved

Regulatory requirements:

Companion diagnostic required (PIK3CA mutation test)

Oncology clinical trial package (Phase I–III)

Risk management plan (RMP)

Labeling requirements:

Severe hyperglycemia warning

Rash and pneumonitis risk

Embryo-fetal toxicity warning

11. Storage & Stability

Store at 20–25°C

Protect from moisture

Shelf life: ~24 months

Stability risks:

Humidity-induced degradation

Polymorphic changes

Photostability generally acceptable

12. Packaging Knowledge

Alu-Alu blister packs (moisture protection)

High-barrier HDPE bottles (some markets)

Oncology safety packaging (child-resistant optional but common)

13. Safety & Toxicology

Common adverse effects:

Hyperglycemia (dose-limiting)

Rash

Diarrhea

Fatigue

Nausea

Serious risks:

Severe hyperglycemia → ketoacidosis risk

Pneumonitis

Severe hypersensitivity reactions

Monitoring:

Blood glucose (mandatory)

HbA1c baseline & follow-up

14. Market & Commercial Knowledge

Market type:

Precision oncology / targeted therapy market

Competition:

Endocrine therapy combinations

CDK4/6 inhibitors (different pathway)

Other PI3K inhibitors (limited due to toxicity issues)

Key driver:

Companion diagnostic-based prescription model

15. Intellectual Property (IP)

Strong composition-of-matter patent (Novartis origin)

Companion diagnostic exclusivity supports lifecycle extension

Secondary patents:

Combination therapy

Specific dosing regimens

16. Environmental & EHS Knowledge

Potent cytotoxic/oncology handling precautions

API manufacturing requires containment systems

Waste:

Genotoxic waste classification possible

Worker safety:

Closed-system handling recommended

17. Export Documentation Knowledge

Required:

DMF (Type II API)

GMP certificate (high-potency API compliance)

COA (batch release)

Stability Bulk alpelisib API Supplier in Vlore studies (ICH Q1A)

Genotoxic impurity assessment

Bioequivalence study (generic)

MSDS (cytotoxic handling guidance)

18. Business Development Knowledge

Opportunities:

Oncology hospital supply chains

Precision medicine oncology programs

Emerging markets oncology expansion

Strategy:

Partner with diagnostic labs (mutation testing)

Oncology specialist physician networks

Value-based pricing (high-cost therapy)

19. Advanced Technical Knowledge

PI3K pathway is central to tumor survival signaling

Mutation-specific therapy = precision oncology model

Resistance mechanisms include pathway reactivation

Hyperglycemia mechanism linked to insulin signaling interference

Narrow therapeutic index in real-world use

20. AI & Digital Knowledge (Modern Pharma)

AI applications:

Companion diagnostic prediction models

Oncology response prediction (mutation-driven ML models)

Real-world evidence (RWE) tracking

Pharmacovigilance signal detection (hyperglycemia risk patterns)

Digital pharma:

Genomic-guided prescription platforms

Hospital oncology decision-support systems

21. Sales Team Product Knowledge Checklist

Sales teams must know:

Only for PIK3CA-mutated breast cancer

Always combined with fulvestrant

Blood glucose monitoring requirement

High toxicity management importance

Companion diagnostic necessity

22. Most Important Technical Documents

DMF (API + formulation)

Clinical trial data (SOLAR-1 study)

Companion diagnostic validation reports

Stability studies (ICH Q1A)

Impurity profiling (ICH Q3A/B)

Genotoxicity assessment

Risk Management Plan (RMP)

GMP certificate

23. Ultimate Pharma Product Mastery Summary

Alpelisib is:

A precision oncology PI3Kα inhibitor

Technically complex due to:

High-dose oral formulation

Toxicity management (hyperglycemia)

Commercially advanced due to:

Companion diagnostic-driven therapy

High-value oncology market

Clinically important in:

Mutation-driven breast cancer treatment

Report this page